Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study

BACKGROUND: For a majority of patients with metastatic colorectal cancer (mCRC) with MS stable (MSS) or mismatch repair proficient (pMMR), the role of immunotherapy is undetermined. This study investigated the efficacy and safety of camrelizumab when added to XELOX chemotherapy plus bevacizumab or r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Hong, Wang, Yuehui, Lin, Yanfang, Cai, Wenjie, Li, Xiaofeng, He, Xiaomeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657606/
https://www.ncbi.nlm.nih.gov/pubmed/34900725
http://dx.doi.org/10.3389/fonc.2021.774445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657606/
https://www.ncbi.nlm.nih.gov/pubmed/34900725
http://dx.doi.org/10.3389/fonc.2021.774445

Ejemplares similares